Division of Haematology-Oncology and Stem Cell Transplantation, Children's Hospital, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland.
Unit for Coagulation Disorders, Department of Haematology, Comprehensive Care Center and Cancer Center, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland.
Thromb Haemost. 2018 Aug;118(8):1390-1396. doi: 10.1055/s-0038-1661394. Epub 2018 Jun 30.
Coagulation system is disturbed by several mechanisms after allogeneic haematopoietic stem cell transplantation (HSCT). We evaluated the effect of HSCT on coagulation system by various conventional and investigational methods in 30 children and adolescents who received HSCT due to haematological malignancies. Pro-thrombin fragment 1 + 2, a specific measure of thrombin generation, and von Willebrand factor, a measure of endothelial activation, increased after conditioning treatment, and remained elevated until 3 months after HSCT ( < 0.05 for all comparisons to pre-conditioning treatment). D-dimer, a measure of fibrin turnover, was elevated from the second week onwards until 4 weeks after HSCT ( < 0.05). Endogenous thrombin potential was increased after conditioning, and at 2 weeks after HSCT ( < 0.05). Furthermore, the activities of acute phase reactants fibrinogen and coagulation factor VIII were increased ( < 0.05 for all comparisons to pre-conditioning treatment) from the first week onwards up to 3 weeks and 3 months after HSCT, respectively. Taken together, paediatric patients receiving HSCT demonstrate distinct and prolonged variations in the coagulation system towards a pro-coagulant state. This shift is of importance when estimating the risk of haemostatic and thrombotic complications in these children.
在异基因造血干细胞移植(HSCT)后,凝血系统会受到多种机制的干扰。我们通过各种常规和研究方法评估了 30 名因血液系统恶性肿瘤而接受 HSCT 的儿童和青少年的凝血系统的影响。凝血酶原片段 1+2 是凝血酶生成的特定指标,血管性血友病因子是内皮细胞激活的指标,在预处理后增加,并在 HSCT 后 3 个月内保持升高(与预处理相比,所有比较均<0.05)。纤维蛋白分解产物 D-二聚体从第二周开始升高,直到 HSCT 后 4 周(与预处理相比,所有比较均<0.05)。内源性凝血酶潜能在预处理后增加,在 HSCT 后 2 周增加(与预处理相比,所有比较均<0.05)。此外,急性反应物质纤维蛋白原和凝血因子 VIII 的活性从第一周开始升高,直到 HSCT 后 3 周和 3 个月,分别升高(与预处理相比,所有比较均<0.05)。总之,接受 HSCT 的儿科患者的凝血系统表现出明显且持久的变化,向促凝状态转变。在评估这些儿童发生止血和血栓并发症的风险时,这种变化很重要。